title: Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection.
abstract: This study was designed to evaluate the short-term safety of implanting sustained-release 5-fluorouracil (5-FU) into hepatic cross-section and omentum majus after primary liver cancer resection and its impact on related indexes of liver. Forty patients were selected and divided into an implantation group (n = 20) and a control group (n = 20). On the first day after admission, first week after surgery, and first month after surgery, fasting venous blood was extracted from patients for measuring hematological indexes. The reduction rate of alpha fetoprotein (AFP) on the first week and first month after surgery was calculated, and moreover, drainage volume of the abdominal cavity drainage tube, length of stay after surgery, and wound healing condition were recorded. We found that levels of alanine aminotransferase, aspartate amino transferase, blood urea nitrogen, creatinine, total bilirubin, albumin, and white blood cells measured on the first week and first month after surgery, length of stay, and wound healing of patients in the two groups had no significant difference (P >0.05). Drainage volume and reduction rate of AFP of two groups were significantly different on the first week and first month after surgery (P <0.05). Implanting sustained-release 5-FU into hepatic cross-section and omentum majus after primary liver cancer resection is proved to be safe as it has little impact on related indexes.
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Jiangtao
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Junjie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Chenyu
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Kunhou
authors.initials: K
authors.lastname: Yao
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Long
authors.initials: L
authors.lastname: Hua
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, China cjt0617@yahoo.com.
authors.forename: Xuequn
authors.initials: X
authors.lastname: Ren
mesh_terms: D000410:Alanine Transaminase / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000378:metabolism; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D009852:Omentum / Q000187:drug effects* / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D003692:Delayed-Action Preparations; D000509:alpha-Fetoproteins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005472:Fluorouracil
keywords: fluorouracil; primary liver cancer; safety